BP aren't stupid.
They know what a normal placebo effect is.
So we have the new depression finding AND a cognition outcome which was good except for the control arm. That's far from being a disaster.
The immediate problem is funding. Now the SP is below the options exercise price, so options exercise revenue can't be counted upon. There will.have to be a CR soon.
[INTERVIEW] Actinogen Medical reveals XanaCIDD phase 2a trials, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $66.72M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $34.32K | 1.606M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 3166166 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 867640 | 4 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| ACW (ASX) Chart |